跳至主要内容
临床试验/RBR-103p86cv
RBR-103p86cv进行中(未招募)4 期

The impact of using MPFF 1000mg/day in improving symptoms, complications and quality of life in patients with CVD under sclerotherapy: a prospective randomized study

MEDCOG Treinamentos, Locações e Organizações de Eventos em Angiologia e Cirurgia Vascular Ltda0 个研究点开始时间: 2024年2月26日最近更新:
适应症

试验速览

阶段
4 期
状态
进行中(未招募)
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18Y 至 60Y(—)

入选标准

  • Pacients aged between 18 and 60 years; of both genders; with Chronic Venous Disease – CVD; able to understand and sign (or their representative) the Informed Consent Form ICF

排除标准

  • Patients with insufficient perforating veins or saphenous veins (magna and/or parva) detected on ultrasound examination; pregnancy; puerperium; peripheral arterial disease; known thrombophilia; previous history of thrombosis; use of anticoagulants; allergy to polidocanol; active infectio; history of asthma and migraine

研究者

发起方
MEDCOG Treinamentos, Locações e Organizações de Eventos em Angiologia e Cirurgia Vascular Ltda

相似试验